DHR vs. GSK: Danaher vs. GSK Stock Comparison

Company Profile

Danaher (DHR) and GSK (GSK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while GSK is classified in Pharmaceuticals.

Danaher (DHR) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Danaher (DHR) at 8.19% and GSK (GSK) at 28.27% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Danaher (DHR) at 16.91% and GSK (GSK) at 12.97% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Danaher (DHR) at 21.13% and GSK (GSK) at 32.14% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Danaher (DHR) at 2.90% and GSK (GSK) at 4.11% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

GSK (GSK) at 123.15% sits in the top EPS growth quartile, while Danaher (DHR) at -4.54% is closer to the peer norm — faster per-share earnings growth for GSK.

Growth Metrics

Financial Strength

Both Danaher (DHR) at 1.63 and GSK (GSK) at 0.86 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Danaher (DHR) at 0.52 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Danaher (DHR) at 0.67% and GSK (GSK) at 1.57% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Danaher (DHR) at 25.17% and GSK (GSK) at 63.33% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Both Danaher (DHR) at 38.12 and GSK (GSK) at 17.54 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Danaher (DHR) at 6.32 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Danaher (DHR) at 3.02 and GSK (GSK) at 4.02 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics